TABLE 2.
Comparisons of the characteristics of patients undergoing hemodialysis with HFpEF before and after initiating sacubitril/valsartan with observation period of 3–12 months.
| Variables | Before sacubitril/valsartan | After sacubitril/valsartan | P-value |
| Clinical parameters | |||
| SBP (mmHg) | 149.7 ± 23.6 | 137.2 ± 21.0 | <0.001 |
| DBP (mmHg) | 90.2 ± 16.1 | 84.5 ± 14.1 | <0.001 |
| Heart rate (bpm) | 83.5 ± 12.5 | 80.0 ± 8.7 | <0.001 |
| Laboratory values | |||
| Hemoglobin (g/L) | 98.1 ± 22.9 | 101.5 ± 20.9 | 0.088 |
| TC (mmol/L) | 3.9 (3.3, 4.6) | 4.0 (3.3, 4.7) | 0.806 |
| TG (mmol/L) | 1.2 (0.8, 1.7) | 1.1 (0.8, 1.6) | 0.605 |
| HDL-C (mmol/L) | 2.5 (1.9, 3.1) | 2.3 (1.7, 3.0) | 0.273 |
| LDL-C (mmol/L) | 1.0 (0.8, 1.4) | 1.5 (1.1, 2.0) | 0.161 |
| Urea (mmol/L) | 27.2 (20.6, 32.8) | 25.2 (19.1, 31.9) | 0.409 |
| Creatinine (μmol/L) | 975.5 (811.0, 1187.1) | 935.0 (726.2, 1150.5) | 0.899 |
| Uric acid (μmol/L) | 386.0 (328.8, 466.0) | 376.0 (302.5, 460.0) | 0.533 |
| Potassium (mmol/L) | 4.4 ± 0.8 | 4.4 ± 0.8 | 0.279 |
| Calcium (mmol/L) | 2.2 (2.0, 2.3) | 2.2 (2.1, 2.3) | 0.127 |
| Phosphorus (mmol/L) | 2.0 (1.6, 2.4) | 1.9 (1.5, 2.4) | 0.547 |
| Hyperkalemia [n (%)] | 14 (5.7%) | 20 (8.1%) | 0.286 |
| Intact PTH (pg/mL) | 261.2 (167.8, 414.6) | 258.0 (149.0, 433.0) | 0.335 |
| Albumin (g/L) | 35.1 ± 5.5 | 36.5 ± 6.0 | 0.009 |
| NT-proBNP (pg/ml) | 29125.0 (11474.5, 68532.0) | 12561.3 (4035.0, 37575.0) | <0.001 |
| Cardiac troponin I (μg/L) | 0.044 (0.025, 0.078) | 0.037 (0.020, 0.064) | 0.009 |
| Creative kinase MB (U/L) | 13.8 (10.1, 19.0) | 14.0 (10.9, 18.0) | 0.471 |
| Cardiac function | |||
| NYHA functional classification | |||
| I | 0 (0.0%) | 110 (44.5%) | <0.001 |
| II | 130 (52.6%) | 82 (33.2%) | |
| III | 117 (47.4%) | 55 (22.3%) | |
| IV | 0 (0.0%) | 0 (0.0%) | |
| Cardiac structure | |||
| RVDd (mm) | 17.2 ± 3.0 | 16.8 ± 2.8 | 0.107 |
| LVPWT (mm) | 11.8 ± 2.0 | 10.8 ± 1.9 | <0.001 |
| IVSd (mm) | 11.8 ± 2.0 | 11.2 ± 2.0 | <0.001 |
| LVDd (mm) | 53.8 ± 6.9 | 51.2 ± 7.1 | <0.001 |
| LAD (mm) | 40.5 ± 6.2 | 37.2 ± 7.2 | <0.001 |
| AAO (mm) | 33.9 ± 4.1 | 32.5 ± 4.9 | 0.001 |
| E/A ratio | 0.8 (0.7, 1.3) | 0.9 (0.8, 1.3) | 0.008 |
| LVEDV (mL) | 143.0 (111.5, 174.0) | 130.0 (105.0, 163.0) | <0.001 |
| LVESV (mL) | 57.0 (43.0, 82.5) | 48.0 (38., 74.0) | <0.001 |
| TRVmax (m/s) | 2.7 (2.5, 3.2) | 2.4 (2.0, 2.8) | <0.001 |
| Septal e’ wave velocity (cm/s) | 8.0 ± 0.6 | 8.2 ± 0.5 | 0.001 |
| Lateral e’ wave velocity (cm/s) | 9.9 ± 0.8 | 10.2 ± 0.7 | <0.001 |
| E/e’ | 8.3 (6.4, 11.8) | 7.2 (6.1, 8.9) | <0.001 |
| LA volume index (mL/m2) | 37.9 ± 4.2 | 36.4 ± 4.1 | <0.001 |
| PASP (mmHg) | 39.0 (30.5, 50.0) | 28.0 (21.0, 37.5) | <0.001 |
| PAH [n (%)] | 145 (58.7%) | 71 (28.7%) | <0.001 |
| LVEF (%) | 61.4 ± 4.6 | 60.3 ± 6.7 | 0.058 |
Data presented as median (first-third interquartile range) or mean ± SD or number (percentage).
HFpEF, Heart failure with preserved ejection fraction; SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beat per minute; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Intact PTH, intact parathyroid hormone; NT-proBNP, N- terminal B- type natriuretic peptide precursor; NYHA functional classification, New York Heart Association Functional Classification; RVDd, right ventricle diastolic diameter; LVPWT, left ventricular posterior wall thickness; AAO, ascending aorta; LVEDV, Left ventricular end-diastolic volume; LVESV, Left ventricular end-systolic volume; E/A ratio, Early-to-late transmitral flow ratio; IVSd, intraventricular septal thickness in diastole; LAD, left atrial diameters; LVDd, left ventricular end-diastolic diameter; TRVmax, maximal tricuspid regurgitation velocity; LA volume index, left atrial volume index; PASP, pulmonary arterial systolic pressure; PAH, pulmonary arterial hypertension; LVEF, left ventricular ejection fraction.